M Rizwan Sohail1, Elizabeth L Eby2, Michael P Ryan1, Candace Gunnarsson1, Laura A Wright1, Arnold J Greenspon1. 1. From the Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN (M.R.S.); CRHF HEOR, Reimbursement and Evidence, Medtronic, Plc, Mounds View, MN (E.L.E.); Health Economics and Outcomes Research (M.P.R., C.G.) and Regulatory & Scientific Affairs (L.A.W.), CTI Clinical Trial and Consulting Services, Inc, Cincinnati, OH; and Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA (A.J.G.). 2. From the Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN (M.R.S.); CRHF HEOR, Reimbursement and Evidence, Medtronic, Plc, Mounds View, MN (E.L.E.); Health Economics and Outcomes Research (M.P.R., C.G.) and Regulatory & Scientific Affairs (L.A.W.), CTI Clinical Trial and Consulting Services, Inc, Cincinnati, OH; and Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA (A.J.G.). Elizabeth.eby@medtronic.com.
Abstract
BACKGROUND: Because of the increasing use of cardiac implantable electronic devices (CIEDs), it is important to estimate the incidence and annual healthcare expenditures associated with CIED infections. METHODS AND RESULTS: Patients with a record of an initial or replacement (full implant or generator only) CIED implant during the calendar years 2009 to 2012 in MarketScan Commercial Claims and Medicare Supplemental database were identified. CIED infections were classified into 4 categories: (1) infection not managed by inpatient admission nor implant removal, (2) infection managed by inpatient admission but no implant removal, (3) infection managed by an implant removal either in an inpatient or in an outpatient setting, and (4) infection with severe sepsis and managed in an inpatient setting with implant removal. Using separate models for initial and replacement cohorts, annualized incidence of infection and incremental annual expenditures by treatment intensity were estimated. Cumulative incidence of infection at 1 year post implant was 1.18% for initial CIED implants and 2.37% for replacement. Median time to infection was 35 days for initial and 23 days for replacement. Incremental healthcare expenditures by treatment intensity categories for initial implant patients at 1 year were $16 651, $104 077, $45 291, and $279 744. For replacement patients, incremental expenditures at 1 year by treatment intensity categories were $26 857, $43 541, $48 759, and $362 606. CONCLUSIONS: The management of CIED infections results in a substantial healthcare burden with a significant increase in annual expenditures the year after implant when device infection occurs.
BACKGROUND: Because of the increasing use of cardiac implantable electronic devices (CIEDs), it is important to estimate the incidence and annual healthcare expenditures associated with CIED infections. METHODS AND RESULTS:Patients with a record of an initial or replacement (full implant or generator only) CIED implant during the calendar years 2009 to 2012 in MarketScan Commercial Claims and Medicare Supplemental database were identified. CIED infections were classified into 4 categories: (1) infection not managed by inpatient admission nor implant removal, (2) infection managed by inpatient admission but no implant removal, (3) infection managed by an implant removal either in an inpatient or in an outpatient setting, and (4) infection with severe sepsis and managed in an inpatient setting with implant removal. Using separate models for initial and replacement cohorts, annualized incidence of infection and incremental annual expenditures by treatment intensity were estimated. Cumulative incidence of infection at 1 year post implant was 1.18% for initial CIED implants and 2.37% for replacement. Median time to infection was 35 days for initial and 23 days for replacement. Incremental healthcare expenditures by treatment intensity categories for initial implant patients at 1 year were $16 651, $104 077, $45 291, and $279 744. For replacement patients, incremental expenditures at 1 year by treatment intensity categories were $26 857, $43 541, $48 759, and $362 606. CONCLUSIONS: The management of CIED infections results in a substantial healthcare burden with a significant increase in annual expenditures the year after implant when device infection occurs.
Authors: Hossein Aslian; Tomas Kron; Troy Watts; Cagla Akalanli; Nicholas Hardcastle; Peta Lonski; Atousa Montaseri; Barry Hay; James Korte; Kemal Berk; Francesco Longo; Mara Severgnini Journal: J Appl Clin Med Phys Date: 2020-04-11 Impact factor: 2.102
Authors: Jordana K Schmier; Edmund C Lau; Jasmine D Patel; Juergen A Klenk; Arnold J Greenspon Journal: J Interv Card Electrophysiol Date: 2017-11-06 Impact factor: 1.900
Authors: Fozia Zahir Ahmed; Catherine Fullwood; Mahvash Zaman; Ahmed Qamruddin; Colin Cunnington; Mamas A Mamas; Jonathan Sandoe; Manish Motwani; Amir Zaidi Journal: PLoS One Date: 2019-01-02 Impact factor: 3.240